Geilen C C, Orfanos-Boeckel H, Offermann G, Orfanos C E
Klinik und Poliklinik für Dermatologie, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin.
Hautarzt. 2000 Feb;51(2):63-9. doi: 10.1007/s001050050013.
Mycophenolate mofetil represents a new immunosuppressive drug. Several case reports have shown that mycophenolate mofetil has a good therapeutic effect in patients with psoriasis and autoimmune dermatoses. Mycophenolate mofetil is a morpholine ester of mycophenolic acid which was shown in the 1970s to be effective in patients with severe psoriasis. Mycophenolate mofetil has an increased bioavailability as compared to mycophenolic acid and thereby an improved therapeutic window. Currently, mycophenolate mofetil is indicated for the prevention of organ rejection in transplant patients. The mode of action and the pharmacology of mycophenolate mofetil are reviewed and the current clinical experience with this immunosuppressive drug for dermatological disorders is summarized.
霉酚酸酯是一种新型免疫抑制药物。多项病例报告表明，霉酚酸酯对银屑病和自身免疫性皮肤病患者具有良好的治疗效果。霉酚酸酯是霉酚酸的吗啉酯，20世纪70年代已证明其对重度银屑病患者有效。与霉酚酸相比，霉酚酸酯的生物利用度更高，因此治疗窗更宽。目前，霉酚酸酯用于预防移植患者的器官排斥反应。本文综述了霉酚酸酯的作用方式和药理学，并总结了这种免疫抑制药物治疗皮肤病的当前临床经验。
